EASI POEM and DLQI: Eczema severity assessment
A practical guide to assessing atopic dermatitis
For dermatology nurses, doctors and pharmacists
EASI, POEM and DLQI capture different aspects of atopic dermatitis: clinical signs, patient-reported symptoms and the impact on daily life. Using them together can give a more complete account of eczema than any one score alone. This guide explains their roles in eczema severity assessment and how to interpret them during an adult review. [1–5]
EASI vs POEM vs DLQI at a glance
Measure | What it captures | Who completes it | Time frame and range |
EASI | Extent and severity of clinical signs | Trained assessor | Current examination; 0 to 72 |
POEM | Frequency of eczema symptoms | Patient or appropriate caregiver | Previous 7 days; 0 to 28 |
DLQI | Effect of skin disease on quality of life | Patient aged 16 or over | Previous 7 days; 0 to 30 |
Sources: HOME, the EASI practical guide, the POEM development study and Cardiff University. [1–5]
What the EASI score measures
The Eczema Area and Severity Index (EASI) grades erythema, oedema or papulation, excoriation and lichenification in four regions: head and neck, upper limbs, trunk and lower limbs. Each sign is graded from 0 to 3. The regional extent of eczema is converted into an area score from 0 to 6. [2,6]
Regional scores combine the sum of the four sign grades, the area score and a body-region weighting. For adults, the weights are 0.1 for head and neck, 0.2 for upper limbs, 0.3 for trunk and 0.4 for lower limbs. The total ranges from 0 to 72. Use the official age-appropriate form when assessing children. [2,6]
EASI describes examination findings. It does not directly measure itch, sleep loss or quality of life. A numerical improvement therefore needs to be considered alongside the patient’s account. [1,2]
Practical scoring points in eczema severity assessment
Assess average sign severity within each region, rather than scoring only the worst patch. Distinguish active eczema from residual pigmentation or dryness alone. Erythema assessment requires care across skin tones; use the published guidance and training resources rather than relying only on how bright red the skin appears. [2,6]
What the POEM score measures
The Patient-Oriented Eczema Measure (POEM) asks about the frequency of seven symptoms over the previous week: itching, sleep disturbance, bleeding, weeping or oozing, cracking, flaking, and dryness or roughness. Each item contributes 0 to 4 points, giving a total of 0 to 28. [3]
POEM captures the patient’s experience between appointments. It measures how frequently symptoms occurred; it is not a direct measure of itch intensity. Self-completed and caregiver-reported versions are available from the University of Nottingham. [3,7]
POEM score | Published interpretation |
0 to 2 | Clear or almost clear |
3 to 7 | Mild eczema |
8 to 16 | Moderate eczema |
17 to 24 | Severe eczema |
25 to 28 | Very severe eczema |
These symptom-severity bands come from the POEM interpretability study. They should not be treated as equivalent to an EASI category or as prescribing criteria. [4]
What the DLQI score measures
The Dermatology Life Quality Index (DLQI) has 10 questions about the effect of skin disease on life during the previous week. It is intended for people aged 16 years and over and produces a total from 0 to 30, with higher scores indicating greater impact. It is dermatology-specific, rather than eczema-specific. [5]
DLQI score | Published impact on life |
0 to 1 | No effect |
2 to 5 | Small effect |
6 to 10 | Moderate effect |
11 to 20 | Very large effect |
21 to 30 | Extremely large effect |
Source: Cardiff University. These bands describe quality-of-life impact, not the severity of visible inflammation. Follow the official scoring rules, including the special handling of the work or study question and incomplete questionnaires. [5]
Evidence and its limitsin eczema severity assessment
The HOME core outcome set for eczema trials separates clinical signs, symptoms, quality of life and long-term control. EASI, POEM and DLQI address the first three domains in adults; they do not constitute a complete assessment of long-term control. This research framework should not be presented as a requirement to collect all three at every clinical visit. [1]
A worked example of differing eczema scores
Illustrative scenario, not a real patient: an adult attends follow-up after a recent flare. Today’s EASI is 6, POEM is 20 and DLQI is 14. The skin has improved since treatment was restarted several days earlier, but the patient describes disrupted sleep and difficulty managing work during the preceding week.
POEM 20 falls within the severe symptom band, while DLQI 14 indicates a very large effect on life. The relatively low current EASI does not invalidate either result: the measures cover different domains and time frames. [1,4,5]
Practical interpretation and measuring change
First, clarify the chronology. Ask when the flare peaked, when treatment changed and which problems remain. Then review individual questionnaire responses and examine sites that matter particularly to the patient. Check scoring technique if the examination and recorded EASI do not fit.
At follow-up, consider both the size of the score reduction and the problems that remain. Minimal clinically important difference (MCID), or minimal important change (MIC), estimates help interpret whether improvement is likely to matter clinically. They should be considered alongside baseline severity and the patient’s experience. [8–10]
For DLQI, a reduction of at least 4 points is a commonly used benchmark for meaningful improvement in inflammatory skin disease. [5,8]
For POEM, a reduction of around 3 to 4 points can help interpret improvement. A 4-point reduction provides a more conservative practical benchmark, although published estimates vary with the population and method used. The 3.4-point estimate comes from Schram et al.; Howells et al. interpreted a change of 3 to 3.9 points as probably clinically important and at least 4 points as very likely clinically important. The Howells analysis involved children with moderate-to-severe eczema, so it should not be treated as a universal adult threshold. [9,10]
For EASI, record the current absolute score alongside improvement from baseline. EASI-50 and EASI-75 describe reductions of at least 50% and 75%, respectively. These response measures describe improvement in clinical signs; they are not MCID thresholds and do not establish symptom relief or acceptable disease control on their own. [11]
Interpret all changes alongside residual symptoms, daily-life impact and the patient’s priorities. These benchmarks should not be used alone to determine treatment escalation or continuation.
The useful outcome is a documented explanation of the discrepancy and an agreed plan. Neither dismiss the symptom burden because the skin looks better nor escalate treatment automatically because a questionnaire score is high.
Using the scores in an eczema review
· Record the assessment date, current treatment and timing of recent changes.
· Use the appropriate official forms and allow patients to report their own experience.
· Interpret signs, symptoms and daily-life impact separately before drawing conclusions.
· Compare with previous results, retaining the absolute scores and the patient’s priorities.
· Document the clinical interpretation, agreed actions and follow-up arrangements.
This is a suggested consultation workflow, not a validated combined scoring algorithm. Do not add EASI, POEM and DLQI together. Treatment selection requires clinical assessment and the applicable treatment guidance or service pathway; this article does not define eligibility thresholds.
Frequently asked questions about EASI POEM and DLQI
What is the difference between EASI POEM and DLQI?
EASI records the extent and severity of clinical signs seen during examination. POEM records how often the patient experienced seven eczema symptoms during the previous week. DLQI records how a skin condition affected an adult patient’s life during the previous week. The measures describe related but distinct domains. [1–3,5]
Which eczema score should I use?
Choose the instrument according to the question you need to answer. Use EASI for clinical signs, POEM for patient-reported symptom frequency and DLQI for the effect on an adult patient’s quality of life. More than one measure may be useful when the domains are relevant to the consultation. [1]
What does it mean when EASI POEM and DLQI scores disagree?
Different results can be clinically plausible because the instruments measure different domains and use different time frames. Clarify when the flare and any treatment changes occurred, review the individual responses and check scoring technique. The discrepancy should be interpreted and documented rather than resolved by choosing the highest or lowest score.
What change in EASI POEM or DLQI is clinically meaningful?
For DLQI, a reduction of at least 4 points is a commonly used benchmark in inflammatory skin disease. For POEM, a reduction of around 3 to 4 points can support interpretation, with 4 points providing a more conservative practical benchmark. EASI-50 and EASI-75 describe reductions of at least 50% and 75% from baseline. These thresholds measure change in different domains and should be interpreted with the patient’s clinical context. [5,8–11]
Can EASI POEM and DLQI scores be added together?
No. They use different scales and measure different constructs. Record and interpret each score separately. There is no validated combined total produced by adding EASI, POEM and DLQI.
Can POEM replace a clinical examination?
POEM supplies patient-reported information about symptom frequency. It cannot establish the diagnosis or replace examination when clinical assessment is needed. [3,7]
How often should EASI POEM and DLQI be repeated?
Repeat assessment when the result will help evaluate disease activity, treatment response or the patient’s experience. Match the interval to the clinical purpose and recall period. POEM and DLQI both ask about the previous seven days; Cardiff University advises allowing at least seven days between DLQI assessments. EASI is a current clinical assessment. [2,3,5]
Can EASI POEM and DLQI be used in children?
EASI can be used in children, but the body-region weighting differs for children under 8 years, so use the official age-appropriate form. POEM has self-completed and caregiver-reported versions. The adult DLQI is designed for people aged 16 years and over; use an appropriate paediatric quality-of-life instrument for younger children. [1,2,5–7]
Continue your dermatology learning
Explore Bright Med’s dermatology education to develop practical skills for your next eczema consultation.
Educational information for healthcare professionals. These measures support assessment and do not replace clinical judgement or individualised care.
References
Clinical references for publication with the article. Online resources checked 13 September 2026.
1. Harmonising Outcome Measures for Eczema (HOME). HOME Core Outcome Set. Core domains and instruments for clinical trials.
2. Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index—A Practical Guide. Dermatitis. 2022;33(3):187–192. doi:10.1097/DER.0000000000000895.
3. Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: Development and Initial Validation of a New Tool for Measuring Atopic Eczema Severity From the Patients’ Perspective. Archives of Dermatology. 2004;140(12):1513–1519. doi:10.1001/archderm.140.12.1513.
4. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. British Journal of Dermatology. 2013;169(6):1326–1332. doi:10.1111/bjd.12590.
5. Cardiff University. Dermatology Life Quality Index. Official administration, scoring and interpretation guidance.
6. Harmonising Outcome Measures for Eczema (HOME). How to Use EASI. EASI guidance v3, January 2017.
7. University of Nottingham, Centre of Evidence Based Dermatology. Patient Oriented Eczema Measure. Official versions and use information.
8. Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27–33. doi:10.1159/000365390.
9. Howells L, Ratib S, Chalmers JR, Bradshaw L, Thomas KS; CLOTHES trial team. How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods. British Journal of Dermatology. 2018;178(5):1135–1142. doi:10.1111/bjd.16367.
10. Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. doi:10.1111/j.1398-9995.2011.02719.x.
11. Williams HC, Schmitt J, Thomas KS, et al.; HOME Initiative. The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology. 2022;149(6):1899–1911. doi:10.1016/j.jaci.2022.03.017.
